Taysha Gene Therapies (TSHA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
12 figures withheld by our checks. Each blank figure names its reason.
37.7mn → 319.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲97% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
-1115¢ of every revenue dollar becomes profit.
Net margin -1115.3% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 5.5 | 9.8 | 8.3 | 15.5 | 2.5 | 0.0 | ▲17.3% | +57.5% (22→25) |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 0.0 | — | — |
Research & development | 126.2 | 86.4 | 66.0 | 56.8 | 91.2 | 131.9 | ▲30.9% | −10.0% |
Selling, general & admin | 43.8 | 33.9 | 29.0 | 30.0 | 37.4 | 41.3 | ▲17.0% | −4.9% |
Total operating expenses | 166.5 | 120.3 | 99.8 | 87.9 | 164.9 | 173.3 | ▲20.5% | −8.7% |
Operating incomefeeds ROC rank | −161.0 | −110.5 | −91.5 | −72.4 | −162.4 | −173.3 | ▼20.8% | — |
Other income, net | 5.0 | 1.5 | 2.2 | −39.1 | −3.6 | −1.3 | — | — |
Pretax income | −156.0 | −109.0 | −89.3 | −111.6 | −166.0 | −174.5 | ▼22.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −156.0 | −109.0 | −89.3 | −111.6 | −166.0 | −174.5 | ▼22.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.43 | −0.34 | −0.36 | −0.96 | −3.78 | −4.64 | ▲5.6% | — |
Diluted shares (mn) | 406.11 | 319.71 | 250.13 | 116.12 | 43.95 | 37.65 | ▲27.8% | +70.7% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | — | — | — |
Operating margin | −2935.4% | −1130.6% | −1097.6% | −468.8% | −6492.7% | — | ▼33.1pp | +5362.0pp |
Net margin | −2844.6% | −1115.3% | −1071.6% | −722.1% | −6635.3% | — | ▼43.6pp | +5520.0pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Taysha Gene Therapies' revenue last fiscal year?
Taysha Gene Therapies reported revenue of $9.8M in fiscal 2025, up 17.3% from fiscal 2024.
What was Taysha Gene Therapies' net income?
Taysha Gene Therapies reported net income of −$109.0M in fiscal 2025, a net margin of −1115.3%.

